Navigation Links
FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update

ATLANTA, Ga., April 9, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting at the inaugural Atlanta Clinical Cardiology Update (CCU), presented by the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University, April 13-14, 2012. The inaugural meeting will provide a new, needs-based and convenient forum for knowledge exchange between general and sub-specialist cardiologists across the spectrum of cardiovascular disease.  

FirstMark will showcase its new cardiovascular test PREvent at the meeting. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant stable CAD. The test is an exciting development in cardiovascular medicine, providing a simple solution for the huge unmet need of assessing CAD patients risk of near term myocardial infarction.

"One of the goals of the inaugural Atlanta CCU meeting is to give attendees the opportunity to catch up on recent clinical trials that are likely to influence practice, presented at conferences such as the American Heart Association and American College of Cardiology Scientific Sessions. The clinical trial for PREvent, was conducted at Emory University and presented at both of these conferences in oral Poster Presentations," said Thomas Silberg, President and CEO of GenWay Biotech. "The final data is quite remarkable, and we are excited for the opportunity to once again highlight the study and present the test."

About PREvent
PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

For additional information, please visit

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development
and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

Media Contact: Deborah Moore GenWay Biotech, 858-458-0866,

News distributed by PR Newswire iReach:

SOURCE GenWay Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
2. BIO-key(R) International Exhibiting at AABB TXPO
3. BIO-key(R) International Exhibiting at AABB TXPO
4. Exposure to young triggers new neuron creation in females exhibiting maternal behavior
5. Penn presents inaugural symposium on applied mathematics and computational science
6. Massague honored with inaugural AACR Distinguished Leadership Award in Breast Cancer Research
7. Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research
8. George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
9. George Whitesides accepts inaugural Dreyfus Prize in the Chemical Sciences
10. International AIDS Society announces inaugural recipients of innovative HIV research awards
11. Inaugural Herbert A. Fleisch ESCEO-IOF Medal is awarded to Professor Gerard Karsenty
Post Your Comments:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: